Cost-utility analysis of tislelizumab in the second -line treatment of advanced or metastatic esophageal squamous cell carcinoma
- VernacularTitle:替雷利珠单抗二线治疗晚期或转移性食管鳞状细胞癌的成本-效用分析
- Author:
Shixian LIU
1
,
2
,
3
;
Shunping LI
1
,
2
,
3
;
Lei DOU
1
,
2
,
3
;
Kaixuan WANG
1
,
2
,
3
;
Zhao SHI
1
,
2
,
3
;
Ruixue WANG
1
,
2
,
3
;
Xiaohong ZHU
1
,
2
,
3
;
Zehua SONG
1
,
2
Author Information
1. Centre for Health Management and Policy Research，School of Public Health，Cheeloo College of Medicine，Shandong University，Jinan 250012，China
2. NHC Key Lab of Health Economics and Policy Research （Shandong University ），Jinan 250012，China
3. Center for Health Preference Research，Shandong University，Jinan 250012，China
- Publication Type:Journal Article
- Keywords:
tislelizumab;
advanced or metastatic esophageal squamous cell carcinoma;
cost-utility analysis;
Markov model
- From:
China Pharmacy
2022;33(18):2250-2255
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the cost -effectiveness of tislelizumab in the second -line treatment of advanced or metastatic esophageal squamous cell carcinoma （ESCC）in China .METHODS A three -state Markov model was constructed to assess the cost -effectiveness of tislelizumab versus chemotherapy in the second -line treatment of advanced or metastatic ESCC and programmed death receptor 1（PD-L1）positive patients . The cycle length of the model was 1 month，and the time horizon of the model was set as 10 years. The discount rate of cost and utility was 5%. One-way sensitivity analysis ，probability sensitivity analysis and scenario analysis were used to verify the robustness of the base -case analysis results . RESULTS The results of the base-case analysis showed that compared with chemotherapy ，the incremental cost -effectiveness ratio （ICER）of tislelizumab in the second-line treatment of advanced or metastatic ESCC and PD -L1-positive patients were 26 864.01 yuan/QALY and 37 510.07 yuan/QALY，respectively，which was much lower than 1 time per capita gross domestic product （GDP）in 2021（80 976 yuan）. Results of scenario analysis showed that the ICER was less than 1 times per capita GDP ，regardless of the chemotherapy regimens（paclitaxel，docetaxel or irinotecan ）used. With the extension of the simulation time limit ，the ICER of tirelizumab regimen gradually decreased ，and the reduction rate gradually E-mail：lishunping@sdu.edu.cn decreased，but they were all less than 1 time China ’s per capita GDP in 2021. The results of the one -way sensitivity analysis showed that the 3 parameters with the most significant impact on the ICER were progression -free survival of tislelizumab group ，price of tislelizumab ，and the proportion of patients receiving follow-up treatment in the tislelizumab group . The results of the probability sensitivity analysis showed that the probability of tislelizumab with cost -effectiveness in the treatment of advanced or metastatic ESCC patients and PD -L1-positive patients were 99.09% and 99.94%，respectively，when using 3 times per capita GDP as the willingness -to-pay threshold . CONCLUSIONS Tislelizumab has economic advantages over chemotherapy alone in the second -line treatment of advanced or metastatic ESCC patients.
